Biomarkers
Modulation of microRNA expression levels after naturally occurring asbestiform fibers exposure as a diagnostic biomarker of mesothelial neoplastic transformation.
Ecotoxicology and Environmental Safety 2020 April 21 [Link] Filetti V, Falzone L, Rapisarda V, Caltabiano R, Eleonora Graziano AC, Ledda C, Loreto C Abstract Fluoro-edenite (FE) is a silicate mineral identified in the lava products of Monte Calvario from stone quarries located in the southeast of Biancavilla, a small city of the Etnean volcanic complex…
Read MoreExtracellular vesicles as biomarkers in malignant pleural mesothelioma: A review.
Critical Review in Oncology and Hematology 2020 April 9 [Link] Ahmadzada T, Kao S, Reid G, Clarke S, Grau GE, Hosseini-Beheshti E Abstract Extracellular vesicles (EV) are secreted by all cells, including cancer cells, as a mode of intercellular transport and communication. The main types of EV known to date include exosomes, microvesicles and apoptotic…
Read MoreCirculating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.
Frontiers in Oncology 2020 April 3 [Link] Ferrari L, Carugno M, Mensi C, Pesatori AC Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer, which originates from the mesothelial cells of the pleura and is associated with asbestos exposure. In light of its aggressive nature, late diagnosis and dismal prognosis, there is an…
Read MoreMicroRNAs diagnostic and prognostic value as predictive markers for malignant mesothelioma.
Archives of Environmental and Occupational Health 2020 April 20 [Link] Sturchio E, Berardinelli MG, Boccia P, Zanellato M, Gioiosa S Abstract Malignant mesothelioma is an aggressive tumor resistant to current therapies with a latency period ranging between 20 and 60 years, caused by inhalation of asbestos fibers, that continues to represent a social and healthcare…
Read MoreTumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition.
Scientific Reports 2020 April 1 [Link] Ghanim B, Rosenmayr A, Stockhammer P, Vogl M, Celik A, Bas A, Kurul IC, Akyurek N, Varga A, Plönes T, Bankfalvi A, Hager T, Schuler M, Hackner K, Errhalt P, Scheed A, Seebacher G, Hegedus B, Stubenberger E, Aigner C Abstract Malignant pleural effusion (MPE) confers dismal prognosis and…
Read MoreImmunotherapy in Malignant Pleural Mesothelioma.
Frontiers in Oncology 2020 February 21 [Link] de Gooijer CJ, Borm FJ, Scherpereel A, Baas P Abstract The only registered systemic treatment for malignant pleural mesothelioma (MPM) is platinum based chemotherapy combined with pemetrexed, with or without bevacizumab. Immunotherapy did seem active in small phase II trials. In this review, we will highlight the most…
Read MoreCurrent evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
Journal of Immunotherapy for Cancer 2020 February [Link] Hotta K, Fujimoto N Abstract Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used as both…
Read MoreExhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review.
International Journal of Environmental Research and Public Health 2020 February 10 [Link] Töreyin ZN, Ghosh M, Göksel Ö, Göksel T, Godderis L Abstract Malignant pleural mesothelioma (MPM) is mainly related to previous asbestos exposure. There is still dearth of information on non-invasive biomarkers to detect MPM at early stages. Human studies on exhaled breath biomarkers…
Read MoreCirculating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival.
Cancers 2020 February 7 [Link]
Read MoreLOX family and ZFPM2 as novel diagnostic biomarkers for malignant pleural mesothelioma.
Biomarker Research 2020 January 8 [Link] Kim MK, Kim HW, Jang M, Oh SS, Yong SJ, Jeong Y, Jung SH, Choi JW Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that develops in the pleural and outer layer of tissues surrounding the lungs. MPM is primarily caused by occupational exposure to…
Read More